MedPath

M.D. ANDERSON CANCER CENTER

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies

Phase 2
Completed
Conditions
Cutaneous T-cell Lymphoma
Chronic Lymphocytic Leukemia
Peripheral T-cell Lymphoma
Interventions
Drug: Deoxycoformycin (DCF)
First Posted Date
2002-05-27
Last Posted Date
2018-11-16
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
60
Registration Number
NCT00038025
Locations
🇺🇸

M. D. Anderson Cancer Center, Houston, Texas, United States

Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening

Phase 3
Completed
Conditions
Adrenal Gland Diseases
Adrenal Gland Neoplasms
First Posted Date
2002-05-24
Last Posted Date
2012-02-22
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
114
Registration Number
NCT00037843
Locations
🇺🇸

University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients

Phase 1
Completed
Conditions
Breast Neoplasms
Metastases, Neoplasm
Interventions
First Posted Date
2002-05-20
Last Posted Date
2012-10-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
35
Registration Number
NCT00037609
Locations
🇺🇸

University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Clofarabine in Chronic Lymphocytic Leukemia

Phase 1
Completed
Conditions
Hematologic Neoplasms
Lymphoproliferative Disorders
Leukemia
Leukemia, Lymphocytic, Chronic
First Posted Date
2002-01-09
Last Posted Date
2015-03-25
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
100
Registration Number
NCT00028418
Locations
🇺🇸

University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath